NEW YORK, July 15, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Vivus Inc. (NASDAQ: VVUS), The Medicines Company (NASDAQ: MDCO), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Amgen Inc. Research Report
On July 9, 2013, Amgen Inc. (Amgen) announced its new collaboration agreement with Servier, leveraging both the Companies' commitment to treat cardiovascular disease. Amgen reported that it has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as Procoralan (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates, as well as an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. The Company stated that S38844 is in Phase 2 studies for the treatment of heart failure. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, said, "A critical unmet medical need remains for patients who don't respond adequately to current available therapies for heart failure and angina. Ivabradine, an If inhibitor, offers a novel alternative approach for patients with elevated heart rates. We value Servier's extensive experience in cardiovascular disease and look forward to working with them as Amgen continues to build our presence in this area." The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/e763_AMGN]
Celldex Therapeutics, Inc. Research Report
On July 10, 2013, Celldex Therapeutics, Inc. (Celldex) announced that the US Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029, 'Human immune therapies using a CD27 agonist alone or in combination with other immune modulators,' which broadly supports the Company's product candidate CDX-1127, a fully human monoclonal antibody (mAb) that targets CD27 and is currently in Phase 1 clinical development for the treatment of solid tumors and hematologic malignancies. Celldex reported that the patent has been assigned to the University of Southampton and that the Company has an exclusive license to the patent based on the execution of an exclusive licensing agreement with the University of Southampton to develop human antibodies to CD27 in November 2008. Tibor Keler, Senior Vice President and Chief Scientific Officer of Celldex, stated, "We continue to make excellent progress advancing CDX-1127 and securing this key piece of intellectual property is an important achievement as we expand our clinical program in solid tumors and complete dose-escalation studies in hematologic malignancies." The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/bd46_CLDX]
Vivus Inc. Research Report
On July 9, 2013, Vivus Inc. (Vivus) announced that it has entered into a License and Commercialization Agreement and a Supply Agreement with Menarini and its wholly-owned subsidiary BERLIN-CHEMIE AG/MENARINI. The partnership aims to commercialize and promote SPEDRA (avanafil) in over 40 European countries, as well as Australia and New Zealand. Timothy E. Morris, Senior Vice President of Global Corporate Development and Finance and Chief Financial Officer of VIVUS, commented, "Menarini has tremendous know how and marketing capabilities throughout Europe and has already established a presence in men's health with the acquisition last year of Priligy (Dapoxetine) for treatment of premature ejaculation (PE). The licensing process was competitive and Menarini was chosen for their extensive presence in their territories and their history of successful drug launches across Europe. We look forward to a long and productive collaboration with Menarini." The Full Research Report on Vivus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/8deb_VVUS]
The Medicines Company Research Report
On July 2, 2013, The Medicines Company announced that it has achieved positive results for its Phase 3 SOLO II clinical trial of oritavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria. Clive Meanwell MD PhD, Chairman and CEO of The Medicines Company, said, "SOLO trial data consistently show that a single dose of oritavancin given on presentation of a patient with ABSSSI to hospital can cure gram positive infections, including MRSA infections, and be at least as efficacious as multiple days of twice-daily vancomycin infusions. The safety profile also appears potentially advantageous over vancomycin. We anticipate submitting an application for oritavancin US market clearance in the fourth quarter of 2013 and a European filing in 2014." The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/518a_MDCO]
Raptor Pharmaceuticals Corp. Research Report
On June 28, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceutical) announced that it has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for PROCYSBI 25mg and 75mg gastro-resistant hard capsules, cysteamine (as mercaptamine bitartrate) for the treatment of proven nephropathic cystinosis. The Company said that if approved, PROCYSBI will be indicated for the treatment of proven nephropathic cystinosis. Christopher M. Starr, Ph.D., CEO of Raptor Pharmaceuticals, stated, "The positive opinion of the CHMP brings us an important step closer to anticipated EU approval of PROCYSBI subject to the European Commission review process." The Full Research Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/a301_RPTP]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports